New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
07:06 EDTISISIsis Pharmaceuticals' ISIS-FXI shows positive Phase 2 data
Isis Pharmaceuticals announced positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events in patients treated with ISIS-FXIRx undergoing total knee replacement surgery, or total knee arthroplasty. ISIS-FXIRx inhibits the production of Factor XI, a coagulation factor that plays a key role in thrombosis. Patients treated with 300 mg of ISIS-FXIRx experienced a seven-fold lower incidence of VTEs compared to patients treated with enoxaparin. Patients treated with 200 mg of ISIS-FXIRx had comparable incidence of VTEs compared to patients treated with enoxaparin. .
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:29 EDTISISIsis Pharmaceuticals earns $4M from Achaogen for Phase 3 study of plazomicin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use